← Back to Search

Telehealth Sociobehavioral Intervention for Opioid Addiction (REAL TTIME Trial)

N/A
Recruiting
Led By Emily Kiernan, DO
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 3 months post intervention, and 1 year post intervention
Awards & highlights

Summary

This trial aims to increase access to treatment for opioid addiction in rural GA by using EDs, GPC physicians, PRCs and RCOs.

Who is the study for?
This trial is for adults over 18 in rural Georgia who speak English and are medically stable, but struggling with opioid use disorder. They should not be currently receiving medication-assisted treatment or psychotherapy for OUD, nor have participated in this study before.Check my eligibility
What is being tested?
The trial tests a new way to help people with opioid addiction by using telehealth in emergency departments. It involves medical toxicologists and peer recovery coaches working together to start treatment and connect patients to ongoing care.See study design
What are the potential side effects?
Since the intervention is sociobehavioral rather than medicinal, traditional side effects like those seen with drugs are not expected. However, participants may experience emotional discomfort or stress during recovery coaching sessions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 3 months post intervention, and 1 year post intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3 months post intervention, and 1 year post intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in number of patients discharged with a prescription for MOUD
Change in number of patients evaluated for MOUD (Medication for Opioid Use Disorder)
Change in number of patients linked to a local RCO (Recovery Community Organization)
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Sociobehavioral program GroupExperimental Treatment1 Intervention
A novel sociobehavioral collaborative program that will improve the health of individuals in rural areas by expanding access to MOUD through an ED- based telemedicine strategy. Researchers will prospectively study a poison center OUD consultation and peer recovery coach (PRC) intervention as it is rolled out at each site, collecting participant-level data at baseline, one week post intervention and 30 days post intervention.
Group II: Control GroupActive Control1 Intervention
Patients who are seen at a participating hospital prior to the initiation of the intervention will be considered controls.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Opioid Use Disorder (OUD) include buprenorphine and naltrexone. Buprenorphine is a partial opioid agonist that binds to opioid receptors, reducing cravings and withdrawal symptoms without producing a significant high. Naltrexone is an opioid antagonist that blocks opioid receptors, preventing the euphoric effects of opioids. These treatments are essential for OUD patients as they help manage withdrawal symptoms and reduce the risk of relapse, facilitating engagement in recovery programs and improving overall quality of life.

Find a Location

Who is running the clinical trial?

Emory UniversityLead Sponsor
1,655 Previous Clinical Trials
2,572,003 Total Patients Enrolled
Emily Kiernan, DOPrincipal InvestigatorEmory University
~320 spots leftby Aug 2026